Radiation therapy after radical prostatectomy: For whom and when?;Radiothérapie post-prostatectomie: Pour quels patients et quand?

Cancer/Radiotherapie

Volumn 6, Issue 3, 2002, Pages 168-174

  Hennequin, C ^a   Ravery, V ^b   Maylin, C ^a   Boccon Gibbod, L ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

Adjuvant irradiation; Prostate carcinoma; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; RADIATION DOSE; REVIEW; TREATMENT INDICATION;

EID: 17144439557     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1278-3218(02)00162-2     Document Type: Short Survey

References (60)

1. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: The first 10 years
2. Radiotherapy vs hormonal therapy for the management of locally recurrent prostate cancer following radical prostatectomy
3. Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: Ten-year update
4. ASTRO consensus panel, Consensus statement: Guidelines for PSA following radiation therapy
5. Pathologic classification of prostate carcinoma. The impact of margin status
6. Is post-operative irradiation after radical prostatectomy necessary?
7. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy
8. Postoperative prostate specific antigen as prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy
9. Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31
10. Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation
11. A multivariate analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer
12. A multivariate analysis of clinical and pathological factors that predicts for prostate specific antigen failure after radical prostatectomy for prostate cancer
13. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy
14. High-grade carcinoma of the prostate: A comparison of current local therapies
15. Correlation of pathologic findings with progression following radical prostatectomy
16. Therapeutic irradiation for patients with an elevated post-prostatectomy prostate specific antigen level
17. Impact of moderate dose of postoperative radiation on urinary continence and potency in patients with prostate cancer treated with nerve sparing prostatectomy
18. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy?
19. Impact of post prostatectomy prostate-specific antigen on outcomes following salvage radiotherapy
20. Impact of surgical margins on prostate cancer recurrence and the use of secondary cancer treatment: Data from the capsure database
21. How to explore the patient with a rising PSA after radical prostatectomy: Defining local versus systemic failure
22. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-Year results
23. Radioimmunoscintigraphy with In-111-labelled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy
24. Serum prostate-specific antigen after post-prostatectomy radiotherapy
25. A preoperative normogram for disease recurrence following radical prostatectomy for prostate cancer
26. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer
27. Correlation of clinical and pathological factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer
28. Stage T1-2 prostate cancer: A multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy
29. Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin
30. Long-term results of radical prostatectomy in clinically localized prostate cancer: Experience at the John Hopkins hospital
31. Local recurrence after radical prostatectomy: Correlation of US features with prostatic fossa biopsy findings
32. Prostate specific antigen and local recureence after radiacl prostatectomy
33. Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: Early versus delayed treatment
34. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer
35. Prostate specific antigen: A critical assesment of the most useful tumor marker for adenocarcinoma of the prostate
36. Combination of prostate-specific antigen, clinical stage, and gleason score to predict pathological stage of localized prostate cancer
37. Evaluation of prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases
38. Irradiation in relapsing carcinoma of the prostate
39. PSA based review of adjuvant and salvage radiation therapy vs observation in postoperative prostate cancer patients
40. Adjuvant radiotherapy in patients with pathologic stage C (pT3N0) adenocarcinoma of the prostate
41. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer
42. Serum prostatic antigen measurement in localized prostatic cancer: Correlation with clinical outcome
43. Natural history of progression after PSA elevation following radical prostatectomy
44. The significance of recurrent PSA after radical prostatectomy: Benign versus malignant sources
45. Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy
46. Adjuvant radiation therapy for recurrent PSA after radical prostatectomy in T1-T2 prostate cancer
47. External beam radiation salvage for residual or recurrent local tumor following radical prostatectomy
48. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer
49. International consultation on Prostatic Intraepithelial Neoplasia and Pathologic staging of Prostatic carcinoma. Workgroup 2: Staging and reporting of prostate cancer - Sampling of the radical prostatectomy specimen
50. The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radiacl prostatectomy
51. The results of radical retropubic prostatectomy and adjuvant therapy for pathologic stage C prostate cancer
52. Adjuvant radiotherapy in patients post-radical prostatectomy with tumor extending through capsule or positive seminal vesicles
53. Radiation therapy for local recurrence of prostate cancer after radical prostatectomy
54. Intensity modulated radiation therapy (IMRT) following prostatcetomy: More favorable acute genitourinary toxicity comprade to primary IMRT for prostate cancer
55. Effect of higher radiation dose on biochemical control after radical prostatectomy for PT3N0 prostate cancer
56. The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: A matched-pair analysis
57. Adjuvant radiation therapy does not cause urinary incontinence after radical prostatcetomy: Results of a prospective randomized study
58. Is post-operative irradiation after radical prostatectomy necessary?
59. Radiotherapy for PSA recurrence after radical prostatectomy